Search

everythinglearnresearchcommunity

for

Search:↓

This study retrospectively reviewed estrogen monotherapy for testosterone suppression in gender diverse individuals assigned male at birth, specifically focusing on transfeminine patients. Out of 10 patients, 7 transfeminine individuals achieved testosterone suppression with serum estradiol levels over 100 pg/mL, using either injectable or transdermal estrogen formulations. Injectable estradiol valerate (4-6 mg weekly) and transdermal patches (0.2 mg twice weekly to 0.3 mg three times weekly) were effective. The study suggests estrogen monotherapy could be a viable alternative to anti-androgens, though the small sample size is a limitation. Further research is needed to confirm these findings and potentially simplify treatment protocols.

This study retrospectively reviewed estrogen monotherapy for testosterone suppression in gender diverse individuals assigned male at birth, specifically focusing on transfeminine patients. Out of 10 patients aged 19-81, 7 transfeminine patients achieved testosterone suppression with serum estradiol levels over 100 pg/mL, using either injectable or transdermal estrogen formulations. Injectable formulations were more common among those who achieved suppression. The study suggests that estrogen monotherapy could be effective without anti-androgens, though the small sample size is a limitation. Further research is needed to explore its potential for simplifying treatment protocols.